biote (BTMD) Competitors

biote (NASDAQ:BTMD) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.

Which has more volatility and risk, BTMD or AVBP?

biote has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in BTMD or AVBP?

21.7% of biote shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 24.0% of biote shares are held by insiders. Comparatively, 18.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to BTMD or AVBP?

In the previous week, ArriVent BioPharma had 2 more articles in the media than biote. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for biote. ArriVent BioPharma's average media sentiment score of 1.12 beat biote's score of 0.78 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BTMD or AVBP more profitable?

biote has a net margin of 5.20% compared to ArriVent BioPharma's net margin of 0.00%. biote's return on equity of -32.41% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	5.20%	-32.41%	22.26%
ArriVent BioPharma	N/A	-43.89%	-29.67%

Which has stronger valuation & earnings, BTMD or AVBP?

biote has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$199.38M	1.09	$3.32M	$0.61	6.51
ArriVent BioPharma	N/A	N/A	-$69.33M	-$3.77	-6.17

Does the MarketBeat Community favor BTMD or AVBP?

ArriVent BioPharma received 8 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 95.83% of users gave ArriVent BioPharma an outperform vote.

Company	Underperform	Outperform
biote	Outperform Votes 15 100.00%	Underperform Votes No Votes
ArriVent BioPharma	Outperform Votes 23 95.83%	Underperform Votes 1 4.17%

Do analysts recommend BTMD or AVBP?

biote currently has a consensus target price of $8.00, suggesting a potential upside of 101.51%. ArriVent BioPharma has a consensus target price of $39.29, suggesting a potential upside of 68.90%. Given biote's higher probable upside, analysts clearly believe biote is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ArriVent BioPharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Summary

biote beats ArriVent BioPharma on 11 of the 18 factors compared between the two stocks.